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Summary 
Human immunodeficiency virus  1 (HIV1) infection is associated with severe psoriasis, B cell 
lymphoma, and Kaposi's sarcoma. A deregulated production of interleukin 6 (IL-6) has been 
implicated in the pathogenesis of these diseases. The molecular mechanisms  underlying the abnormal 
IL-6 secretion of HIVl-infected cells may include  transactivation  of the IL-6 gene by HIV1. 
To test this hypothesis, we used the plL6Pr-chloramphenicol  acetyltransferase (CAT) plasmid, 
an IL-6 promoter-CAT construct, as a target of the transactivating function of the HIV1 TAT 
protein.  By cotransfecting  the pIL6Pr-CAT  and  the tat-expressing  pSVT8  plasmid  in MC3 
B-lymphoblastoid  or in HeLa epithelial cells, we observed that TAT transactivates the human 
IL-6 promoter. These results were confirmed when plL6Pr-CAT  was transfected in MC3 or 
HeLa cells that constitutively expressed the tat gene in a sense (pSVT8 cells) or antisense (pSVT10 
cells) orientation. 5' deletion plasmids of plL6Pr-CAT, in which regions at  -658,  -287, and 
-172 were inserted 5' to the cat gene, were transiently transfected in pSVT10 and pSVT8 cells 
and showed that TAT-induced activation of the IL-6 promoter required a minimal region located 
between - 287 and  - 54 bp. Moreover, experiments with plasmids carrying the  - 658,  - 287, 
and  - 172 bp regions of the IL-6 promoter inserted downstream to a TAR-deleted HIV1-LTR 
identified the sequence of -172 to  -54 as the minimal region of the IL-6 promoter required 
for TAT to transactivate the TAR-deleted HIV1-LTR.  By DNA-protein binding experiments, 
tat-transfected cells expressed a consistent increase in KB and nuclear factor (NF)-IL-6 binding 
activity. Accordingly, the pDRCAT and IL-lkEK9CAT, carrying tandem repeats of NF-KB or 
NF-IL6 binding motifs, respectively,  were activated in TAT-expressing  cells. The biological relevance 
of the TAT-induced IL-6 secretion was addressed by generating 7TD1 cells, an IL-6-dependent 
mouse cell line, stably expressing the tat gene. These tat-positive cells expressed the endogenous 
IL-6 gene, secreted high amounts of murine IL-6, and grew efficiently in the absence of exogenous 
IL-6. Moreover, the tat-positive  7TD1 cells sustained the growth of parental 7TD1 cells and 
showed a dramatic increase in their tumorigenic potency. These results suggest that TAT protein 
may play a role in the pathogenesis of some HIVl-associated diseases by modulating the expression 
of host cellular genes. 
H 
IVI infection causes various clinical and immunolog- 
ical abnormalities,  including lymphadenopathy,  acti- 
vation  of polyclonal  B  cells that  manifests  as  hypergam- 
maglobulinemia and auto-antibody production, Kaposi's sar- 
coma, and lymphoma of the B  cell phenotype (1-3).  In 
HIVl-infected subjects, there is a deregulated production of 
cytokines, that affects the growth and differentiation of lym- 
phoid and mesenchymal  ceils, and that may contribute to the 
development of the clinical features of AIDS. IL-6 has a broad 
range of biological effects (4) and plays a major role in the 
development  of B cell malignancies  and Kaposi's sarcoma (5-7). 
IL-6 gene transcription  is induced in ceils infected by HIV1, 
and increased levels of IL-6 have been reported in serum and 
cerebral spinal fluid of HIVl-infected patients (8-10). These 
findings suggest that HIV1  may transactivate the host cel- 
lular  IL-6 gene. 
The TAT protein of HIV1  is required  for efficient viral 
gene expression (11). TAT increases  the initiation of transcrip- 
tion from the HIV1-LTR (12) and affects RNA processing 
and utilization by interacting with a TAT-responsive  element 
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to the initiation site (+ 1) of viral transcription (13). In addi- 
tion, TAT interacts with upstream regulatory DNA sequences 
circumscribed within the nuclear factor (NF)t-rB/Sp1  re- 
gion of the HIV1 promoter (14) and with host cell proteins 
(15-19). TAT could affect the transcription of cell genes such 
as IL-6, whose regulatory sequences, like HIV1-LTR, possess 
NF-rB and NF-IL6 enhancer elements (20, 21). To test this 
hypothesis, we used the plL6Pr-CAT,  an IL-6 promoter-CAT 
construct, as a target of the transactivating function of the 
HIV1 TAT proteins. By cotransfecting the plL6Pr-CAT and 
the  tat-expressing  pSVT8  plasmids  (22)  in  MC3 
B-lymphoblastoid or in HeLa epithelial cells, we observed 
that TAT transactivated the human IL-6 promoter.  These 
results were confirmed when plL6Pr-CAT was transfected 
in MC3 or HeLa cells that constitutively expressed  the tat 
gene. The biological relevance of the tat-induced  IL-6 secre- 
tion was addressed  by generating 7TD1  cells, an IL-6-de- 
pendent mouse cell line (23), stably expressing the tat gene. 
These tat-positive  cells expressed the endogenous IL-6 gene, 
grew efficiently in the absence of exogenous IL-6, and showed 
a dramatic increase  in their tumorigenic potency. 
Materials and Methods 
Animals and Reagents.  4-wk-old  female nude mice were pur- 
chased from Charles River Breeding Laboratories (Como, Italy). 
LPS Escherichia coli 055:B55 was obtained from Difco Laboratories 
(Detroit, MI). G418 (Geneticin, 658 #g of G418 base per mg) was 
purchased from Sigma Chemicals  (Milan, Italy). Recombinant TAT 
protein and the rabbit anti-TAT antibody were obtained from the 
National Institutes of Health-AIDS Research and Reference Re- 
agent Program. Rat monoclonal and goat polyclonal antibodies 
to mouse IL6 were purchased from Boehringer Mannheim (Milan, 
Italy) and from Genzyme  (Cambridge, MA), respectively.  Elisa  assays 
specific for human or mouse IL-6 were purchased from Genzyme. 
HPLC-purified human  rlL-6 (sp  act,  2.7  ￿  109  U/mg)  was 
provided by G. Ciliberto (Istituto di Ricerche  di Biologia  Molecolare, 
Pomezia, Italy). 
Plasmids.  To generate the plL6Pr-CAT plasmid, the 1.2 Kbp 
BamH1-Xhol 5' upstream sequences of the IL-6 gene were excised 
from the pGEMB672A plasmid (24) and inserted into compatible 
sites (BamHI-SalI) of the pEMBL-CAT  plasmid  using standard  tech- 
niques (25). The 5' deletion mutants of plL6Pr-CAT were gener- 
ated by digesting the plL6Pr-CAT with Bali, NheI, or HaellI, fol- 
lowed by fill-in with Klenow polymerase. The resulting constructs 
contained regions of -658,  -287, and  -172 relative to the first 
nucleotide of the ATG codon of the IL-6 genomic sequence (24). 
To generate the HIV1-LTR-IL-6 promoter  fusion plasmids, the 
TAR-deleted EcoRI-BgllI fragment of pILC-CAT (26) was iso- 
lated, filled-in, and inserted at the SstI site (filled) of the various 
IL-6 promoter mutants. The correct 5'-3' orientation was analyzed 
by multiple restriction digestions and by sequencing using the 
Sanger's method (25). The pSVT8 and pSVT10 plasmids, expressing 
the tat gene in a sense or antisense orientation, respectively (22), 
were obtained  from A. Caputo (University  of Ferrara, Ferrara, Italy). 
The/3-galactosidase  expressing  pnls-lacZ  plasmid  was obtained  from 
A.  Weisz (University of Naples, Naples, Italy). The pDRCAT 
ptasmid, carrying the HIVI-rB enhancer upstream to a thymidine 
Abbreviations used in this paper: CAT, chloramphenicol  acetyltransferase; 
NF, nuclear factor; nt, nucleotide. 
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kinase (tk) basal promoter was provided  by W. Greene (University 
of California at  San  Francisco, San  Francisco, CA).  The  IL- 
1REK9CAT plasmid, carrying three copies of the NF-IL6 binding 
motif upstream to the IL-6 basal promoter, was donated by T. 
Kishimoto and T. Hirano (University  of Osaka, Osaka,  Japan). The 
plLC-CAT plasmid, carrying the HIV1-LTR and TAR region, and 
the pSV12 plasmid, harboring the tat gene, were a kind gift of A. 
Rabson (Center for Advanced Biotechnology and Medicine, Pis- 
caraway, NJ). 
Cells,  Transfection  Procedures,  and  Analysis  of  the  Transfected 
Cells.  IM9, a human myeloma cell line (American Type Culture 
Collection, Kockville,  MD), EBV-positive  MC3 (6), and HeLa ep- 
ithelial ceils were cultured in DMEM supplemented with 10% 
vol/vol heat-inactivated FCS (Flow Laboratories, Milan, Italy), 3 
mM glutamine, and 10 mM Hepes buffer, pH 7.2 (Gibco Labora- 
tories, Milan, Italy). The IL-6-dependent  7TD1 cells (23) were cul- 
tured as previously reported (6). MC3 and HeLa  cells were trans- 
fected by electroporation as previously described (6, 27). Briefly, 
cells were washed and resuspended in 0.8 ml of Ca  2+- and Mg  2+- 
free PBS (D-PBS) at a concentration of 1.5  ￿  107/ml in the pres- 
ence of 10 #g of pSV2neo control plasmid, pSVT8 or pSVT10 
plasmids linearized  by ScaI digestion. Cells were subjected to a single 
electrical pulse (0.2 kV, 960 #FD) using an apparatus (Bio-Rad 
Laboratories, Milan, Italy), recovered, and cultured for 48 h in 
DMEM supplemented  with 10% FCS before selection  in 3 mg/ml 
G-418 (Geneticin). Cells were routinely cultured in G-418-sup- 
plemented medium. The integration of the transfected plasmids 
was analyzed as described (27). High molecular weight DNA was 
isolated, digested with SalI or BamHI enzymes, electrophoresed 
in 0.6% agarose gel, blotted on filters (Gene Screen Plus; Du Pont, 
Milan, Italy), and analyzed by Southern blotting  using either a 
0.3-Kbp tat probe excised from the pSV12 plasmid by BgllI diges- 
tion, or a 1.1-kbp EcoRI neo fragment isolated from the pSV2-neo 
plasmid. Specific tat- and human 13-actin mRNAs from pSVT10- 
or pSVT8-transfected cells were analyzed by reverse transcription 
of total RNAs, followed  by PCR ampli-fication  using the tat primers 
5'-TTACTCCACACACCACACCAAGAA-3'  and 5'-TCTCTC- 
TCTCTCTCCACCTTCTTCTTCTAT-3', and with the [3-actin 
primers 5 '-ATGGATGATGATATCGCCGCG-3'  and 5 '-CTAGAA- 
GCATTTGCGGTGGACGATGGAGGGGCC-3'.  Specific tat 
R.NAs were visualized  by electrophoresis  in 1.5% agarose  gel. The 
presence of transactivating TAT proteins was tested by transiently 
expressing the HIV1-LTR containing plLC-CAT plasmid (25) in 
mock-transfected  cells and in cells expressing the tat gene in a sense 
or antisense  orientation. The expression of the plL6Pr-CAT  plasmid 
in tat- or antitat-positive  MC3 and HeLa cells was analyzed  by tran- 
siently transfecting cells with different amounts of plL6Pr-CAT 
as detailed in the legend to the figures. 7TD1 cells were cultured 
in IL-6-supplemented  medium as reported (6, 23), and transfected 
with the pSV2neo, pSVT8, or the pSVT10 plasmid. 48 h after trans- 
fection, cells were cultured in the presence of 2 mg/ml G-418 
(Geneticin). 2 wk later, cells were tested for tat gene integration 
and for the presence of tat transcripts and TAT transactivating pro- 
teins as detailed above. Cells were then cultured without exoge- 
nous Ib6. The expression of the endogenous mouse IL-6 gene was 
analyzed  by RNA reverse transcription  and PCR amplification  using 
the  primers: 5'-ATGAAGTTCCTCTCTGCAAGGACT-3', and 
5'-CACTAGGTTTGCCGAGTAGATCTC-Y.  Amplified PCR 
products were electrophoresed  in 1% agarose gel, transferred  onto 
nylon membranes (Gene Screen Plus) and hybridized with a 0.6- 
kbp EcoRI-HindlII  fragment of mouse IL-6 eDNA probe (28). 
7TDI-pSV2neo control cells were generated  by transfection  of 7TD1 
cells with pSV2neo followed by G418 selection in the presence of 
exogenous IL-6. To evaluate the capacity of the 7TDI-pSVT8 cell 
HIV1-TAT Activates the 11:6 Gene to sustain the growth of the IL-6-dependent 7TDl-pSV2neo cells, 
7TDl-pSVneo cells were cultured (4  x  103 cells/well in 0.2 ml 
cultures) with 25% vol/vol of conditioned medium from 7TD1- 
pSVT8 cells in the absence of exogenous IL-6. Cell growth was 
evaluated after 72 h by cell counting and [3H]thymidine incorpo- 
ration as previously reported (6).  In other experiments, 7TD1- 
pSV2neo cells were cocultured at 2  x  105 cells/ml with 7TD1- 
pSVT8 cells (2  x  105 cells/ml) in transwell plates,  where 7TD1 
cells (upper level) were separated  by a 0.45-/zm membrane from 
the tat-transfected 7TDI-pSVT8 cells (lower level). In these experi- 
ments, 7TD1 cells were counted daily. In other experiments, 7TD1 
cells were cultured in the presence of 50 ng/ml of human IL-6 or 
with amounts of recombinant TAT protein ranging from 0.3 to 
10/zg/ml. In parallel experiments, tat-positive  7TDI-pSVT8 cells 
were cultured in the presence of a rabbit polyclonal antibody to 
TAT at concentrations ranging from 1:100 to 1:1,000 final dilu- 
tion. The proliferative rate was analyzed at 72 h as described  (6). 
For transient expression  experiments, cells were transfected by 
electroporation at 5  x  106 cells in 0.8 ml of D-PBS as detailed 
above and cultured for 48 h in complete DMEM medium.  The 
amounts  of transfected  DNA  were  equalized  either  with  the 
pZipSVneo  control  plasmid  or  with  pUC18  plasmid  DNA. 
Moreover, in preliminary experiments, we found that cell transfec- 
tions generated CAT activity that was linear in the range of 5 to 
70 #g/ml of pSV2-CAT, after which it declined.  Under these con- 
ditions, CAT activity in cellular extracts from duplicate transfec- 
tions varied by <15%.  Transfection efficiency was monitored by 
cotransfecting the cells with 5 #g of pnls-lacZ plasmid,  fl-Gal ac- 
tivity was assayed using 80-100 #g of protein cell extract as de- 
scribed (25). A random 25% variation of the fl-Gal levels was ob- 
served throughout this study. The transient expression experiments 
were performed at least five times with different plasmid prepara- 
tions.  Primer extension was carried out as described (25).  20 #g 
of total KNA was annealed to the oligonucleotides 5'-CAACGG- 
TGGTATATCCAGTG-Y (for cat RNA),  and  5'-CAGATACTA- 
CACTTG-Y (for U2 RNA). RNA was elongated with reverse tran- 
scriptase,  digested  with  RNase  A  and  separated  over  a  6% 
denaturating 7 M urea-acrylamide gel. 
CAT Assays.  48 h after transfection, cells were harvested and 
washed once with PBS. Cell extracts were prepared by three cycles 
of freeze-thawing in 0.25 M Tris, pH 7.8, and CAT assays were 
performed as previously described (27, 29). Proteins were measured 
in each cell extract with an assay kit (Bio-Rad) and equal amounts 
of proteins were analyzed for each sample.  Each assay contained 
50 #g of  cell extract, 20 #1 of  4 mM acetyl-coenzyme  A (Boehringer 
Mannheim), 1 #1 (0.5 #Ci) of I)-threo-(1.2-14C)-chloramphenicol 
(NEN, Boston, MA) in a final volume of 150/~1 of 0.25 M Tris, 
pH 7.8. Reactions were incubated for 3 h at 37~  extracted with 
ethyl acetate, dried, and spotted on silica gel plates (Polygram Sil 
G; Macherey-Nagel, Duren, Germany). Plates were run in a tank 
containing a mixture of chloroform/methanol (95:5). After a 16-h 
autoradiography, the plates were cut and samples were counted in 
a scintillation counter (LS5000TD; Beckman Instruments,  Inc., 
Palo Alto, CA). 
Electrophoretic Mobility Shift Assays (EMSA).  Nuclear extracts 
and gel shift assays were performed as described elsewhere (27, 29). 
After incubation, cells were harvested, washed once in cold PBS, 
and transferred to 1.7-ml microfuge tubes for a second wash in 
cold PBS. The supematant was removed and the cell pellet was 
resuspended in lysing buffer (10 mM Hepes, pH 7.9, 1 mM EDTA, 
60 mM KC1, I mM dithiothreitol (DTT), I mM PMSF, and 0.2% 
vol/vol NP-40 for 5 rain. Nuclei were collected by centrifugation 
(500 g for 5 rain), rinsed with NP-40-free lysing buffer, and re- 
suspended  in 150 #1 of buffer containing 250 mM "Iris HC1, pH 
7.8, 20% glycerol, 0.42 M NaC1, 60 mM KCI, 1 mM DTT, and 
1 mM PMSF. Nuclei were then subjected to three cycles of freezing 
and thawing. The suspension was cleared by centrifugation (7,000 
g for 15 min), and aliquots were immediately tested in a gel retarda- 
tion assay or stored in liquid phase N2 until use. Oligonucleotide 
probes used included 5'-GATCGGACGTCACATTGCACAATC- 
TTAATAAT-3  (NF-IL-6),  5-GGACGTCACACTACAAACTCT- 
TAATAA-3' (mutant NF-IL6), 5'-TGGGATTTCCCA-3 (rB), and 
5-TAATATTTTCCCA-3' (mutant KB). Each oligonucleotide was 
annealed to its complementary strand and end-labeled with 3,_[32]. 
ATP (Amersham Corp., Arlington Heights, IL) using polynucleo- 
tide kinase (New England Biolabs, Beverly, MA). Equal amounts 
of cell extracts were incubated in a reaction mixture consisting of 
20 #1 buffer containing 20 mM Hepes, pH 7.9, 20% glycerol, 100 
mM KC1, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 2/~g 
poly (d[I-C]) (Boehringer Mannheim), and 5 #g of extract for 5 
min on ice. 1 #1 of "y-32p-labeled double-stranded probe (0.2 ng, 
4-6  x  104 cpm) was then added with or without a 100-fold excess 
of competitor wild type or mutant oligonucleotide. The reactions 
were incubated at room temperature for 30 min and run on a 5% 
acrylamide/bis-acrylamide (30:1) gel in 22.5 mM Tris-borate,  0.5 
mM EDTA. Gels were dried and autoradiographed. 
Results and Discussion 
The HIV1  TAT Protein Transactivates the Promoter of the IL-6 
Gene.  The plL6Pr-CAT was cotransfected with either the 
pSVT8 or the pSVT10 plasmid (22) that carry the tat gene 
in sense and antisense orientation, respectively, and allow G-418 
selection by expressing the neo gene.  As  shown  in Fig.  1, 
a  and b,  the tat gene product efficiently increased the IL-6 
promoter-dependent CAT activity in both B lymphoblastoid 
MC3  and epithelial  HeLa cells.  In  these experiments LPS, 
a likely contaminant of plasmid preparations and a possible 
inducer of IL-6 promoter activity (30), exerted no effect. These 
data suggested that the tat gene, transiently expressed in both 
B lymphoid and epithelial cells, transactivated the promoter 
of IL-6. 
In further experiments, MC3  and HeLa cells were stably 
transfected with either the pSVT8 or the pSVT10 plasmid. 
After selection in G-418,  we obtained stable bulk cultures 
of MC3-pSVT8,  MC3-pSVT10,  HeLa-pSVT8,  and HeLa- 
pSVT10 cells. The integration of the tat gene was tested by 
Southern blots of genomic DNA,  and the tat transcription 
was analyzed by PCR amplification of tat-specific transcripts. 
To ascertain the presence of TAT proteins, we exploited the 
transactivating effects that TAT exerts on HIV1-LTR (11), 
and  conducted  transient  expression experiments  in  which 
pSVT8- or pSVT10-positive ceils were transfected with the 
plLC-CAT, an HIV1-LTR-carrying plasmid (26). These ex- 
periments showed that the transfected MC3 and HeLa cells 
(a) harbored the tat gene in a random genomic integration 
with an average of one copy per cell genome (data not shown); 
(b) efficiently expressed tat-mKNAs  (data not shown);  and 
(c) had a high constitutive activation of the HIV1-LTK-CAT 
plasmid, which indicated the endogenous production of func- 
tional TAT proteins (Fig. 2 a). We used transient expression 
experiments to test whether pSVT8- or pSVT10-transfected 
963  Scala et al. Figure  1.  The tat gene product transactivates the IL6 promoter. (a) HeLa cells were transiently transfected with 10 ttg of plL6Pr-CAT plasmid 
together with the indicated  amounts of  the tat-expressing  pSVT8 plasmid. The percent specific  acetylations,  calculated  by directly counting the acetylated 
spots, were: 0.3 (baseline), 2.2 (1/zg), 6.8 (5/zg), and 16.8 (10/zg). In parallel experiments, cells were transfected  with 10 #g of plL6Pr-CAT plasmid 
and with similar amounts of pSVT10 (anti-tat) plasmid with no significant  variations over  the baseline plL6Pr-CAT expression  (data not shown). The 
data are representative  of several  independent  experiments.  Similar  results  were obtained  by transfecting  MC3 cells  (data not shown). (b) MC3 B-lymphoblastoid 
cells were transfected with 10/~g of plL6Pr-CAT and with 10 #g of the indicated plasmids. At 24 h after transfection, cell aliquots were stimulated 
with Escherichia coli LPS (1 #g/ml)  for additional 24 h. Percent acetylations were: pSV2neo, 0.80 (LPS-), 0.75 (LPS+); pSVT10, 1.10 (LPS-), 1.15 
(LPS  +); pSVTS, 10.5 (LPS-), 10.8 (PLS  +). The data are representative  of several  independent experiments.  Similar  results were obtained by transfecting 
HeLa cells (data not shown). 
cells  transactivated  the  plL6Pr-CAT  plasmid.  Both  MC3- 
pSVT8 and HeLa-pSVT8 produced a higher IL-6 promoter- 
driven CAT activity than did the control pSVT10-transfected 
cells  (Fig.  2  b). 
When the tat-transfected MC3 and HeLa cells were tested 
for the  secretion of IL-6 by specific ELISA  assay,  pSVT8- 
transfected cells secreted a higher amount  of IL-6 than the 
pSV2neo- or pSVT10-transfected cells (Table 1). These data 
indicate that  stable expression of the HIV1  tat gene results 
in  the  activation  of the endogenous  IL-6 gene. 
Identification  of the  Region of the IL-6 Promoter Responsive 
to TAT.  To gain further insights into the molecular mecha- 
nisms  of the TAT-induced activation of the IL-6 gene,  we 
performed  a  primer  extension  analysis  of cat  mRNA  in 
pSVT10- and pSVT8-cells transfected with the plL6pr-CAT 
plasmid.  As  shown  in Fig.  3,  HeLa-pSVT8 ceils expressed 
higher amount  of cat mRNA  than  the anti-tat-transfected 
pSVT10-cells.  The elongated product  extended  for 98  bp, 
locating the transcription start site at  -  63 bp, corresponding 
to the major start site of the IL-6 gene (24). Similar results 
were obtained by primer extension analysis of the IL-6 mRNA 
transcribed from the endogenous IL-6 gene in tat- or anti- 
tat-transfected  MC3  and  HeLa cells  (data  not  shown). 
To address the question of whether TAT could interact with 
IL-6 promoter sequences located upstream to the transcrip- 
tion start site, we constructed 5' deletion mutants of plL6Pr- 
CAT  in  which  regions  at  -658,  -287,  and  -172  were 
inserted  5' to the cat gene (Fig.  4  a).  These plasmids  were 
transiently transfected in pSVT10 and pSVT8 cells and showed 
that the plL6Pr(-287)-CAT plasmid was efficiently transac- 
Figure  2.  Constitutive activation of the IL-6  promoter in HeLa and MC3 cells stably expressing  the tat gene. (a) Constitutive expression  of  pILC-CAT 
in the tat-transfected  cells. Tat (pSVT8)- or anti-tat (pSVT10)-expressing  cells were transiently transfected  with 10 #g of the HIV-1-LTK-carrying  pILC- 
CAT plasmid. Percent acetylations  were: HeLa-pSVT10,  0.6; HeLa-pSVT8,  38.0, MC3-pSVT10, 1.8; MC3-pSVT8, 92.0. (b) Expression  of  plL6Pr-CAT 
plasmid in tat-transfected cells. Cells were transfected with 5/zg (a) or 10 #g (b) of plL6Pr-CAT plasmid. Percent acetylations, calculated 48 h after 
transfection, were: HeLa-pSVT10:  (a) 0.10; (b) 0.15; HeLa-pSVT8: (a), 5.3; (b) 14.0; MC3-pSVT10: (a) 1.0; (b) 2.4; MC3-pSVT8: (a) 12.5; (b) 23.0. 
964  HIV1-TAT  Activates the IL-6 Gene Figure  3.  Primer  extension 
analysis of pIL6Pr-CAT mRNA 
in pSVT10- or pSVT8-transfected 
cells. Anti-tat  (pSVT10)-  or tat 
(pSVT8)-expressing  HeLa cells 
were transfected with  10/xg of 
plL6Pr-CAT plasmid. 36 h later, 
total  RNA  was  isolated  and 
analyzed  by  primer  extension. 
Protected  bands  of cat  and U2 
mRNAs are indicated.  A  24 h 
exposure of U2 band is shown, 
while cat mRNA band is a 4-d 
exposure. (a) HeLa-pSVT10; (b) 
HeLa-pSVTS. 
a 
tivated  by TAT, whereas the plL6Pr(-172)-CAT  construct 
was unresponsive to TAT (Fig.  4 b). This suggests that TAT- 
induced activation of the IL-6 promoter required a minimal 
region located between  -  287 and  -  54 bp (at the XhoI site). 
Next, we generated  plasmids  where the  -658,  -287,  and 
-  172 bp regions of the IL-6 promoter were inserted down- 
stream to a TAR-derived HIV1-LTR sequence. The resulting 
pAILC-IL6Pr-CAT plasmids (Fig.  4 a) were transiently  ex- 
pressed in tat or anti-tat-transfected cells. In these experiments, 
the sequence  of -  172 to  -  54 of the IL-6 promoter was un- 
responsive to TAT (pIL6Pr(-172)-CAT, Fig.  4  b). This se- 
quence, however, conferred TAT responsiveness to the TAR- 
deleted HIV1-LTR  promoter (compare pAILC-CAT and 
pAILC-IL6Pr(-172)-CAT  plasmids in Fig.  4  b). 
A  primer extension analysis of cat mRNA  transcribed by 
the pAILC-IL6Pr(-172)-CAT identified a major protected 
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Figure  4.  (a) Schematic  representation ofpIL6Pr- 
CAT and HIV1-LTP,-IL6  promoter fusion plasmids. 
Restriction  sites are indicated as: (B) BamHI; (BI) 
Bali; (Bg) BgllI; (N) NheI; (H) HaelII; (X) XhoI. 
(b) Induction  of mutant pIL6Pr-CAT and of HIV1- 
LTR-pIL6Pr-CAT fusion plasmids by TAT. 10/~g 
of the indicated plasmids, carrying 5' deletions of 
pIL6Pr-CAT or discrete regions of the Ib6 promoter 
fused to a TAR-deleted HIV1-LTR sequence, were 
transiently  transfected in pSVT10- or pSVT8-HeLa 
cells. CAT activity was assayed at 48 h as detailed 
in Materials and Methods. 
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7TDI  Cells 
Cells  IL-6 secretion (pg/mt) 
MC3-pSV2neo  14.0 
MC3-pSVT10  16.6 
MC3-pSVT8  318 
HeLa-pSV2neo  336 
HeLa-pSVT10  384 
HeLa-pSVT8  1,913 
7TDl-pSV2neo  <3 
7TDI-pSVT8  216 
Mo  +  LPS  2,350 
pSV2neo-transfected  control cells and tat- or anti-tat-transfected  cells were 
cultured for 48 h. Supernatants  were then  collected  and tested  for IL-6 
content by ELISA specific  for human or murine  IL-6. Data express the 
amounts of IL-6 secreted by 106 cells over 48-h culture time. Human 
monocytes  were isolated  by centrifugation  over Ficoll-Hypaque  followed 
by 46% Percoll gradients  and stimulated  with LPS at 1 #g/ml, as described 
elsewhere (45). 
band of 248 nucleotides (nt), corresponding to the start site 
(+ 1) of HIV1-LTR (Fig. 5, lanes a and c). Moreover,  consis- 
tent with the data shown in Fig. 3, the amount of cat mRNA 
in tat-expressing  cells was significantly higher than the cat 
mRNA transcribed by anti-tat-transfected  cells. In fact, both 
the 98-nudeotide cat band generated by transfecting pIL6Pr- 
(-287)-CAT (Fig. 5, lanes b and d), and the 248 nt cat band 
generated by the pAILC-IL6Pr(-172)-CAT (Fig.  5, lanes a 
and c) were highly activated in TAT-positive cells. A longer 
exposure of the primer extension experiments revealed the 
presence  of a 98-nt additional cat band in cells transfected 
with the pAILC-IL6Pr(- 172)-CAT, indicating that the start 
sites of the IL-6 promoter and of the HIV1-LTR were both 
functional. A densitometer analysis of the cat bands revealed 
that the HIV1-LTR start site was preferentially utilized, with 
a minimal transcription from the IL-6 promoter start site (data 
not shown). This suggests that both the plL6Pr(- 287)-CAT 
and the pAILC-IL6Pr(- 172)-CAT plasmids were responsive 
to TAT. Results shown in Fig.  4  b identified the sequence 
of  -172 to  -54  (at the XhoI site)  as the minimal region 
of the IL-6 promoter required for TAT to transactivate the 
ATAR HIV1-LTR. This suggests that the - 172/- 54 bp re- 
gion could function as a TAT-responsive  sequence, possibly 
allowing TAT to be directed close to the TATA box of the 
IL-6 promoter. 
The Expression of the HIV1  tat Gene Induces an Increase in 
NF-xB and NF-IL6 Binding Factors.  The data shown in Fig. 
4 b, where TAT activated the plL6Pr(-287)-CAT  plasmid 
while the plL6Pr(- 172)-CAT was unresponsive to TAT, sug- 
gested that TAT-mediated activation of  the IL-6 gene required 
transcription factors binding sequences located within - 287 
and -54 bp of the IL-6 promoter. In this region, functional 
Figure 5.  Primer  extension  analysis  of  cat mRNA  in pSVT10- or pSVT8- 
cells transfected  with pIL6Pr(-  287)-CAT and of pA1LC-IL6Pr(  - 172)-CAT 
plasmids. Anti-tat (pSVT10)- or tat (pSVT8)-expressing  HeLa  cells were 
transfected with 10/zg of pIL6Pr(-287)-CAT or pAILC-IL6Pr(-172)- 
CAT. 36 h later, total RNA was isolated  and analyzed  by primer exten- 
sion. The 98-nt and the 248-nt cat messages  were  generated  by transfecting 
the pIL6Pr(-  287)-CAT or the pAILC-IL6Pr(-  172)-CAT, respectively.  HeLa 
pSVT10 cells transfected with pAILC-IL6Pr(-172)-CAT (a)  or with 
plL6Pr(-287)-CAT (b); HeLA-pSVT8 cells transfected with pA[LC- 
IL6Pr(-172)-CAT (c) or with pIL6Pr(-287)-CAT (d). A 24-h exposure 
is shown. Similar results were obtained in the case of transfected MC3 
lymphoblastoid cells. 
NF-KB and NF-IL6 enhancers have been identified (20, 21). 
Therefore, we tested whether TAT might induce nuclear factors 
binding to the KB or NF-IL6 sequences of the IL-6 promoter. 
As shown in Fig.  6, tat-transfected  cells expressed a consis- 
tent increase in KB and NF-IL6 binding activity. Accordingly, 
the IL-1REK9CAT and pDRCAT, carrying tandem repeats 
of NF-IL6 or NF-KB binding motifs, were consistently acti- 
vated in TAT-expressing cells (Table 2). In other experiments, 
we also found that suboptimal amounts of the tat-expressing 
pSVT8 plasmid synergized with the pCMV-NFIL6 expres- 
sion vector (21) in inducing a full activation of the IL-6 pro- 
moter (data not shown). 
The Expression of the HIV1  tat Gene in the IL-6-dependent 
7TD1 cells Confers Growth Independency  from IL-6 and Enhanced 
Tumorigenicity.  Deregulated expression of the IL-6 gene has 
been associated with the abnormal growth and tumorigenic 
phenotype of a variety of lymphoid and mesenchymal cells, 
966  HIV1-TAT  Activates the IL-6 Gene Figure 6.  Induction  of NF-~B and NF-IL6  binding factors  by TAT. 10 
/zg of nuclear proteins were tested for binding to the ~B or NF-IL6 se- 
quences of the Ib6 promoter. IM9 is a myeloma  cell line constitutively 
expressing NF-IL6. Only retarded  bands are shown. Competitions  were 
tested with 25-, 50-, or 100-fold  molar concentrations of unlabeled KB 
or mutant ~B (A-KB).  In the NF-IL6  band-shift experiments,  nuclear  ex- 
tracts were  competed  with 50-fold  molar  concentrations  of  unlabeled  NF- 
IL6 (b) or mutant NF-IL6  (c). Similar  results  were  obtained  with MC3 cells. 
including EBV-positive B cell lymphoma and Kaposi's sar- 
coma (4-7) which are common malignancies among HIV1- 
infected patients. In vitro, IL-6 molecules enhance the sur- 
vival and the growth potential of  neoplastic B cells and Kaposi's 
sarcoma cells  and they induce a tumorigenic phenotype in 
immortalized EBV-positive cells (5, 7). To gain further in- 
sight into the biological relevance  of the TAT-mediated in- 
duction of IL-6, we transfected the IL-6-dependent 7TD1 
cells (23) with pSVT8, pSVT10, or pSV2neo control plasmids. 
These cells, which are strictly dependent on exogenous IL-6 
for their growth, were cultured in the presence of optimal 
amounts (20 ng/ml) of human rlL-6 and G-418 for 15 d. 
Isogenic 7TDl-pSVT98 (TAT positive) and 7TDI-pSVT10 
(TAT negative) cells were then cultured without exogenous 
IL-6. Only the tat-expressing  7TDI-pSVT8 cells survived and 
grew efficiently without exogenous IL-6 (shown in Fig.  7 
a). pSVT8- and pSVT10-transfected cells expressed tat-specific 
mP,  NA (Fig. 7 b). Moreover, tat-transfected  cells  showed a 
constitutive activation of plLC-CAT plasmid higher than the 
anti-tat-transfected  cells, indicating that functional TAT pro- 
teins were produced by the tat-expressing cells (Fig. 7 c). These 
tat-positive  cells  expressed IL-6 mRNAs,  whereas control 
7TD1 cells did not express any detectable IL-6 mP,  NAs (Fig. 
7 d). Moreover, 7TD1-pSVT8 cells constitutively secreted con- 
sistent amounts of murine IL-6 (Table  1). 
The IL-6-dependent 7TDl-pSV2neo and 7TDI-pSVT10 
cells could grow both in the presence of conditioned medium 
of 7TDI-pSVT8 cells and when they were cocultured with 
TAT-positive 7TDI-pSVT8 cells in transweU culture plates 
where cell contacts were prevented (data not shown). These 
effects were probably caused by the  IL-6  secreted by tat- 
transfected cells,  rather  than by TAT proteins released  by 
pSVT8-transfected cells. In fact, a polyclonal antibody to TAT 
protein did not inhibit the IL-6-independent growth of TAT- 
positive 7TDI-pSVT8 cells, whereas antibodies to mouse IL-6 
consistently decreased the growth of 7TDI-pSVT8 cells (data 
not shown). Furthermore, recombinant TAT was unable to 
substitute for IL-6 in the growth of 7TD1 parental cells (data 
not shown). These data argue against a direct role of TAT 
as growth factor. 
The expression of the tat gene and the subsequent IL-6-in- 
dependent growth of 7TDI-pSVT8 cells would be expected 
to induce a modulation of the tumorigenic phenotype of the 
TAT-positive 7TD1 cells. This possibility was tested by sub- 
cutaneously injecting either the control 7TDl-pSV2neo or 
the TAT-positive 7TDI-pSVT8 cells in athymic nude mice. 
Table  2.  Constitutive Expression of pDRCA T  and pIL-1REK9CA T  in  tat- or Anti-tat-transfected  HeLa  Cells 
Transfected plasmid  CAT activity* 
Cells  pDRCAT  plL-1REK9CAT  plLC-CAT  Acetylation  Fold inductions 
% 
HeLa pSVT10*  +  -  -  3.2 
HeLa pSVT8  +  -  -  55.4  17.3 
HeLa pSVT10  -  +  0.3 
HeLa pSVT8  -  +  5.7  19.0 
HeLa PSVT10  -  -  +  2.8 
HeLa pSVT8  -  -  +  62.0  22.1 
The data are representative  of five independent experiments. Similar results were obtained in the case of MC3-pSVT10 and MC3-pSVT8 cells. 
* HeLa-pSVT10 (anti-tat-transfected) or HeLa-pSVT8  (tat-transfected) were transiently transfected  with 10/zg of the pDR CAT (carrying two KB 
motifs) or with 10 gg of the plL-1REK9-CAT (carrying three NF-IL6 binding motifs). Cells were also transfected  with 10 #g of plLC-CAT, 
a HIV1-LTR-CAT construct. 
* Determined at 48 h after transfection  by using 50/zg of cell extract. 
$ Expressed as the ratio of percentages acetylated. 
967  Scala et al. Figure  7.  Generation  and characterization  of 7TD1 cells stably  expressing 
the tat gene. (a) 7TD1 cells  were transfected  with pSVT8 or pSVT10  plasmid 
as previously reported (6, 27). G-418 selection (2 mg/ml, Geneticin) was 
applied 48 h after transfection. 2 wk later, cells were cultured without 
exogenous IL-6 whereas G-418 selection was continued. Cells were moni- 
tored daily for growth.  Aliquots of 7TD1 cells were transfected with 
pSV2neo plasmid and cultured in IL6-supplemented medium (data not 
shown).  (b)  Expression of the  transfected tat  gene. Total RNA  from 
pSV2neo, pSVT8-, or pSVT10-transfected  7TD1 cells was amplified  with 
reverse PCR using tat- or 3-actin-specific  primers and visualized by elec- 
trophoresis in 1.5% agarose. (M) BglI-Hinfl digested pBR328; (a) RNA 
from 7TDl-pSV2neo cells; (b and c) RNA from pSVTS- or pSVT10- 
transfected cells. (c) Constitutive expression of the plLC-CAT plasmid in 
7TD1 and 7TDI-pSVT8 cells. 7TDl-pSV2neo (a) and 7TDI-pSVT8 (tat- 
positive cells, b) were transfected with 10 #g of the HIV1-LTR-carrying 
plLC-CAT plasmid. Percent acetylations 48 h after transfection were: (a) 
1.5; (b) 30.4. (d) Expression of the endogenous IL-6  gene in tat-transfected 
7TD1 cells. RNA from 7TDl-pSV2neo (a), 7TDI-pSVT8 (b), and mouse 
spleen cells stimulated for 24 h with  1 #g/ml of LPS (c) was amplified 
by reverse PCR, electrophoresed in agarose gel, transferred onto nylon 
membrane, and hybridized with a mouse IL-6 cDNA probe. 
~t-transfected  7TDI-pSVT8 cells caused a dramatic increase 
in both the number of mice with tumors and in the number 
of tumors per animal (Table 3). These data suggest that TAT 
proteins could play a role in the generation of a tumorigenic 
phenotype by sustaining the autocrine growth of susceptible 
cells. 
In this paper we show that the HIV1 tat gene, either tran- 
siently expressed or stably transduced in MC3 lymphoblastoid 
cells  and  in  HeLa epithelial  cells,  transactivates  the  human 
IL-6 promoter. Moreover, the stable expression of the HIV1 
tat  gene  resulted  in  the  activation  of the  endogenous  IL-6 
gene and in the secretion of consistent amounts of IL-6 mol- 
ecules.  This finding may be of relevance because IL-6 mole- 
cules are secreted by HIVl-infected cells and can increase HIV1 
gene expression  (8,  31),  and because a variety of cell types, 
including B and epithelial cells, can be infected by HIV1 (32, 
33).  The foregoing data suggest that there is a potent auto- 
crine or paracrine mechanism  of stimulation  of HIV1 gene 
expression in which HIV1 infection results in a TAT-mediated 
secretion  of IL-6 molecules,  which  in  turn  enhance  HIV1 
gene expression.  Interestingly, IL-6 gene expression can also 
be triggered by the HIV1 envelope glycoproteins gp120 and 
gp160 (34, 35), suggesting that a deregulated production of 
IL-6 could  take place in the early phase of HIV1 infection, 
and could result in the stimulation of different bystander cell 
types. A recent paper (36) reported that HIV1 infection resulted 
Table  3.  In  Vivo  Tumorigenicity  of tat-tmnsfected  7TD1  Cells 
Cells 
Tumorigenicity in  vivo 
No.  of mice with  tumors/Average  of tumors 
No.  of inoculated  mice  per positive mouse 
7TDl-pSV2neo  1/6  1 
7TDI-pSVT8  6/6  3.0 
Tumorigenicity in nude mice was assayed  by a single subcutaneous injec- 
tion of 2  x  10  6 cells in 0.2 ml of PBS (6). Typically, tumors >5 mm 
in diameter developed after 10-15 d of latency at the challenge site and 
in the regional LN and showed a histological picture of infiltrating blast 
cells (data not shown). Data are the numbers of tumors recorded through 
6 wk of observation. 
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inducer  of IL-6 gene (4), likely through  the TAT protein. 
In the same study,  the  IL-6 production  was not detected, 
suggesting that TAT may selectively activate specific promoters 
in different cell phenotypes. 
The molecular mechanisms whereby TAT activates the IL-6 
gene are at present unknown.  The TAT protein of HIV1 is 
required for efficient viral gene expression (12). TAT increases 
the initiation of transcription from the HIV1 LTR (13) and 
affects RNA processing and utilization by interacting with 
a TAT-responsive element  (TAR) located between nucleo- 
tide  + 1 and  + 44 with respect to the start site (+ 1) of viral 
transcription  (11). TAT could activate IL-6 transcription  by 
interacting with RNA stem-loop structures in the 5' untrans- 
lated region of the IL-6 promoter. At least three functional 
transcription  start sites have been identified in the IL-6 pro- 
moter at  -176,  -86,  and  -63 from the first nucleotide of 
the ATG codon (24).  A  sequence analysis  of these regions, 
carried out using the energy minimizing algorithm of Zuker 
(37), defines a RNA stem-loop structure at the 5' untrans- 
lated region of IL-6 mRNA potentially able to bind to TAT. 
Here we report that the region of the IL-6 promoter located 
at  -172 to  -54 can substitute for the TAR sequence,  al- 
lowing TAT  to transactivate  the TAR-deleted HIV1-LTR. 
Our data suggest that  TAT may be directed at this region 
of the IL-6 promoter by binding to a RNA structure,  and 
could induce the transcription  of the IL-6 gene by possibly 
cooperating with transcriptional factors such as NF-KB and 
NF-IL6. This possibility is currently under investigation. Al- 
ternatively, TAT may bind to cell transcription factors, as re- 
cently suggested (15,  17), and ultimately activate IL-6 tran- 
scription. Another possibility is that TAT could increase the 
stability of a baseline constitutive transcription  of IL-6 gene 
in MC3 and HeLa cells.  However, such posttranscriptional 
activity cannot apply to 7TD1 cells because they do not ex- 
press any detectable IL-6 mRNA. 
Recent reports suggest that TAT cooperates with upstream 
regulatory DNA  sequences circumscribed within  the NF- 
KB/Spl region of the HIV1 promoter (14) and with host cell 
proteins  (15-19).  TAT could affect the transcription  of cell 
genes such as IL-6, whose regulatory sequences, like HIV1- 
LTR, possess NF-KB and NF-IL6 enhancer elements (20, 21). 
In support of this possibility, we found that  expression of 
tat leads to an increase  in KB and NF-IL6 binding  factors. 
In addition,  since  the pIL6Pr(-172)-CAT  plasmid,  which 
lacks a NF-IL6 binding motif but retains a KB site, was not 
induced by TAT, our data suggest that in tat-transfected cells 
NF-KB and NF-IL6 could function as a unique transcriptional 
complex, as recently suggested (38), in activating the IL-6 
promoter. 
A variety of clinical  lesions are associated with HIV1 in- 
fection. This includes B lymphomas, psoriasis,  and Kaposi's 
sarcomas, where HIV1 transcripts  have been detected (1-3, 
39). There is evidence that abnormal secretion of IL-6 plays 
a major role in the pathogenesis of these diseases by cooper- 
ating with such other cytokines as oncostatin M  and IL-1, 
which in turn are potent inducers of IL-6 secretion (4, 40-42). 
In this paper we showed that TAT is a major stimulant  of 
IL-6 secretion and could induce autocrine growth  and en- 
hanced tumorigenicity  of the IL-6-dependent  7TD1  cells. 
These data are consistent with and support the recent obser- 
vations that TAT can activate the transcription of genes from 
heterologous viral and cellular promoters (36, 43, 44), and 
suggest that TAT proteins may directly participate in the patho- 
genesis of HIVl-associated diseases  by modulating  the ex- 
pression of host cellular  genes. 
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